Skip to main content

Advertisement

SpringerLink
Log in

Peptide receptor imaging in neuroendocrine tumors: comparison between diagnostic scintigraphy and post-therapy whole-body scan

  • Original Article
  • Published:
Annals of Nuclear Medicine Aims and scope Submit manuscript

Abstract

Objective

Several different somatostatin analogs labeled with gamma or positron-emitting radionuclides exist for diagnostic imaging of neuroendocrine tumors (NETs). Differences between standard diagnostic scintigraphy (SDS) and post-therapy whole-body scan (PTWBS) at peptide receptor radionuclide therapy in lesion detection are known; such differences have been correlated with the varying degree of receptor subtype expression and the varying receptor affinity profile of the different ligands. The aim of this study is to investigate differences between SDS and PTWBS obtained using the same radiopharmaceutical.

Methods

We retrospectively reviewed clinical records of 53 patients with a diagnosis of NET, who underwent both SDS and PTWBS using 111In-Pentetreotide. We compared the number of lesions for each body region detected by SDS and PTWBS.

Results

In 14/53 patients (26.4 %) discrepancies between SDS and PTWBS were found. PTWBS detected 68 additional lesions with respect to SDS that were distributed as follows: head and neck, 6; mediastinum, 1; liver, 10; abdomen/pelvis, 1; bone, 44; other localizations, 6. The number of lesions detected by SDS was significantly different from that revealed by PTWBS (Wilcoxon matched pairs test, P = 0.0313). The regions that contributed significantly to reach this difference were head and neck (McNemar test, P = 0.0412), liver (McNemar test, P = 0.0044), bone (McNemar test, P < 0.0001) and other localizations (McNemar test, P = 0.0412).

Conclusion

PTWBS shows more lesions than SDS with a significant discrepancy. We suppose that administration of higher radiopharmaceutical activity, use of larger peptide amount and the different time interval between radiopharmaceutical administration and scan execution can determine a higher sensitivity of PTWBS.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

References

  1. Kwekkeboom DJ, Bakker WH, Kooij PP, Konijnenberg MW, Srinivasan A, Erion JL, et al. [177Lu-DOTA0, Tyr3]octreotate: comparison with [111In-DTPA0]octreotide in patients. Eur J Nucl Med. 2001;28:1319–25.

    Article  PubMed  CAS  Google Scholar 

  2. Bombardieri E, Ambrosini V, Aktolun C, Baum RP, Bishof-Delaloye A, del Vecchio S, Oncology Committee of the EANM, et al. 111In-Pentetreotide scintigraphy: procedure guidelines for tumour imaging. Eur J Nucl Med Mol Imaging. 2010;37:1441–8.

    Article  PubMed  Google Scholar 

  3. Al-Nahhas A, Win Z, Szyszko T, Singh A, Khan S, Rubello D. What can gallium-68 PET add to receptor and molecular imaging? Eur J Nucl Med Mol Imaging. 2007;34:1897–901.

    Article  PubMed  Google Scholar 

  4. Basu S, Abhyankar A, Kand P, Kumar R, Asopa R, Rajan MG, et al. “Reverse discordance” between 68Ga-DOTA-NOC PET/CT and 177Lu-DOTA-TATE posttherapy scan: the plausible explanations and its implications for high-dose therapy with radiolabeled somatostatin receptor analogs. Nucl Med Commun. 2011;32:654–8.

    Article  PubMed  CAS  Google Scholar 

  5. Mirzaei S, Bastati B, Lipp RW, Knoll P, Zojer N, Ludwig H. Additional lesions detected in therapeutic scans with 177Lu-DOTATATE reflect higher affinity of 177Lu-DOTATATE for somatostatin receptors. Oncology. 2011;80:326–9.

    Article  PubMed  CAS  Google Scholar 

  6. Minutoli F, Herberg A, Sindoni A, Cardile D, Cucinotta M, Baldari S. Is detection of additional lesions in post-peptide receptor radionuclide therapy scans with respect to diagnostic imaging only due to different affinity of ligands?: a report of discordance between diagnostic and posttherapy imaging using the same ligand. Clin Nucl Med. 2012;37:817–8.

    Article  PubMed  Google Scholar 

  7. Kwekkeboom DJ, Krenning EP, Lebtahi R, Komminoth P, Kos-Kudła B, de Herder WW, Mallorca Consensus Conference participants; European Neuroendocrine Tumor Society, et al. ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: peptide receptor radionuclide therapy with radiolabeled somatostatin analogs. Neuroendocrinology. 2009;90:220–6.

    Article  PubMed  CAS  Google Scholar 

  8. Minutoli F, Herberg A, Sindoni A, Cardile D, Cucinotta M, Baldari S. A potentially misleading finding at somatostatin receptor scintigraphy: focal pulmonary areas of intense accumulation without computed tomography-detectable lung lesions. J Endocrinol Invest. 2012;35:708–9.

    PubMed  CAS  Google Scholar 

  9. Teunissen JJM, Kwekkeboom DJ, Valkema R, Krenning EP. Nuclear medicine techniques for the imaging and treatment of neuroendocrine tumours. Endocr Relat Cancer. 2011;18:S27–51.

    Article  PubMed  CAS  Google Scholar 

  10. Bombardieri E, Coliva A, Maccauro M, Seregni E, Orunesu E, Chiti A, et al. Imaging of neuroendocrine tumours with gamma-emitting radiopharmaceuticals. Q J Nucl Med Mol Imaging. 2010;54:3–15.

    PubMed  CAS  Google Scholar 

  11. Schillaci O, Scopinaro F, Angeletti S, Tavolaro R, Danieli R, Annibale B, et al. SPECT improves accuracy of somatostatin receptor scintigraphy in abdominal carcinoid tumors. J Nucl Med. 1996;37:1452–6.

    PubMed  CAS  Google Scholar 

  12. Whiteman ML, Serafini AN, Telischi FF, Civantos FJ, Falcone S. 111In-octreotide scintigraphy in the evaluation of head and neck lesions. AJNR Am J Neuroradiol. 1997;18:1073–80.

    PubMed  CAS  Google Scholar 

  13. Balon HR, Goldsmith SJ, Siegel BA, Silberstein EB, Krenning EP, Lang O, et al. Procedure guideline for somatostatin receptor scintigraphy with 111 In-pentetreotide. J Nucl Med. 2001;42:1134–8.

    PubMed  CAS  Google Scholar 

  14. Kwekkeboom DJ, Mueller-Brand J, Paganelli G, Anthony LB, Pauwels S, Kvols LK, et al. Overview of results of peptide receptor radionuclide therapy with 3 radiolabeled somatostatin analogs. J Nucl Med. 2005;46:62S–6S.

    PubMed  CAS  Google Scholar 

  15. Cailleux AF, Baudin E, Travagli JP, Ricard M, Schlumberger M. Is diagnostic iodine-131 scanning useful after total thyroid ablation for differentiated thyroid cancer? J Clin Endocrinol Metab. 2000;85:175–8.

    Article  PubMed  CAS  Google Scholar 

  16. Iwano S, Kato K, Nihashi T, Ito S, Tachi Y, Naganawa S. Comparisons of I-123 diagnostic and I-131 post-treatment scans for detecting residual thyroid tissue and metastases of differentiated thyroid cancer. Ann Nucl Med. 2009;23:777–82.

    Article  PubMed  Google Scholar 

  17. Yang J, Codreanu I, Servaes S, Zhuang H. I-131 MIBG post-therapy scan is more sensitive than I-123 MIBG pretherapy scan in the evaluation of metastatic neuroblastoma. Nucl Med Commun. 2012;33:1134–7.

    Article  PubMed  CAS  Google Scholar 

  18. Leners N, Jamar F, Fiasse R, Ferrant A, Pauwels S. Indium-111-pentetreotide uptake in endocrine tumors and lymphoma. J Nucl Med. 1996;37:916–22.

    PubMed  CAS  Google Scholar 

  19. Krenning EP, Bakker WH, Kooij PP, Breeman WA, Oei HY, de Jong M, et al. Somatostatin receptor scintigraphy with indium-111-DTPA-D-Phe-1-octreotide in man: metabolism, dosimetry and comparison with iodine-123-Tyr-3-octreotide. J Nucl Med. 1992;33:652–8.

    PubMed  CAS  Google Scholar 

  20. Castaldi P, Rufini V, Treglia G, Bruno I, Perotti G, Stifano G, et al. Impact of 111In-DTPA-octreotide SPECT/CT fusion images in the management of neuroendocrine tumours. Radiol Med. 2008;113:1056–67.

    Article  PubMed  CAS  Google Scholar 

  21. Perri M, Erba P, Volterrani D, Lazzeri E, Boni G, Grosso M, et al. Octreo-SPECT/CT imaging for accurate detection and localization of suspected neuroendocrine tumors. Q J Nucl Med Mol Imaging. 2008;52:323–33.

    PubMed  CAS  Google Scholar 

Download references

Conflict of interest

No potential conflicts of interest were disclosed.

Author information

Authors and Affiliations

  1. Department of Biomedical Sciences and of Morphologic and Functional Images, University of Messina, Messina, Italy

    Fabio Minutoli, Alessandro Sindoni, Davide Cardile, Mariapaola Cucinotta & Sergio Baldari

  2. Nuclear Medicine Unit, A.O.O.R Papardo-Piemonte, Messina, Italy

    Astrid Herberg

  3. U.O.C. di Medicina Nucleare, A.O.U. Policlinico G. Martino, Via Consolare Valeria 1, 98100, Messina, Italy

    Fabio Minutoli

Authors
  1. Fabio Minutoli
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Astrid Herberg
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Alessandro Sindoni
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Davide Cardile
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Mariapaola Cucinotta
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Sergio Baldari
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Fabio Minutoli.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Minutoli, F., Herberg, A., Sindoni, A. et al. Peptide receptor imaging in neuroendocrine tumors: comparison between diagnostic scintigraphy and post-therapy whole-body scan. Ann Nucl Med 27, 654–660 (2013). https://doi.org/10.1007/s12149-013-0732-6

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12149-013-0732-6

Keywords

Search

Navigation